946822-60-2

Upstream product

• 946825-97-4 10-chloro-2-cyclopentyl-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-5-one 
• 1062244-03-4 3-[(2-chloro-5-nitro-pyrimidin-4-yl)-cyclopentyl-amino]-propanoic acid ethyl ester 
• 928788-22-1 ethyl 3-(cyclopentylamino)propanoate 
• 946825-98-5 2-chloro-9-cyclopentyl-5-methyl-5,7,8,9-tetrahydro-6H-pyrimido[4,5-b][1,4]diazepin-6-one 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 

Downstream Products

• 946822-64-6 tert-butyl 4-[[4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-benzoyl]amino]piperidine-1-carboxylate 

Relevant academic research and scientific papers

Identification of novel, potent and selective inhibitors of Polo-like kinase 1

A series of pyrimidodiazepines was identified as potent Polo-like kinase 1 (PLK1) inhibitors. The synthesis and SAR are discussed. The lead compound 7 (RO3280) has potent inhibitory activity against PLK1, good selectivity against other kinases, and excell

PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound of formula (VII)I, or a pharmaceutically acceptable salt or ester thereof, wherein: X is NR7; Y is O or N-(CH2)nR19; n is 1, 2 or 3; m is 1 or 2; R1 and Rs

POLO-LIKE KINASE INHIBITORS

Compounds of the following formula are provided for use with kinases, wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful

Dihydrodiazepines useful as inhibitors of protein kinases

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, co

NOVEL COMPOUNDS

There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.

SUBSTITUTED PYRIMIDODIAZEPINES

The present invention provides PLK1 inhibitor compounds of formula I: Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the t